Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study

AIM: To evaluate effectiveness of dexamethasone intravitreal implant 0.7 mg (DEX) monotherapy in the AUSSIEDEX study non-responder subgroup, defined by diabetic macular oedema (DME) refractory to anti-vascular endothelial growth factor (anti-VEGF) agents. METHODS: This prospective, open-label, obser...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitchell, Paul, Arnold, Jennifer, Fraser-Bell, Samantha, Kang, Hyong Kwon, Chang, Andrew A, Tainton, Jodi, Simonyi, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Retina
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407411/
https://www.ncbi.nlm.nih.gov/pubmed/37541745
http://dx.doi.org/10.1136/bmjophth-2022-001224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407411/
https://www.ncbi.nlm.nih.gov/pubmed/37541745
http://dx.doi.org/10.1136/bmjophth-2022-001224

Ejemplares similares